AC-NP: A novel chimeric peptide with natriuretic and vasorelaxing actions

12Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

The aim of this study was to evaluate the cardiovascular and renal activities of a newly designed natriuretic peptide (NP). Here, we engineered a novel 28-amino acid chimeric peptide, termed AC-NP that combined the 17-amino acid ring of C type natriuretic peptide (CNP) with the 6-amino acid N-terminus and 5-amino acid C-terminus of atrial natriuretic peptide (ANP). Both in vitro and in vivo experiments were performed to determine the actions of AC-NP. In normal rats, AC-NP proved to be more potentially diuretic, natriuretic and hypotensive compared with other NPs, such as ANP, CNP and vasonatrin peptide (VNP), which is another man-made NP. In relaxation of isolated abdominal aorta from rat, AC-NP was equally effective to ANP, CNP and VNP. Elevated levels of 3′,5′-guanosine monophosphate (cGMP) in plasma and urine cGMP excretion indicated the participation of cGMP in the functions of AC-NP. Taken together, innovative designed AD-NP might be a new candidate therapeutic peptide against cardiorenal disorders. © 2011 Chen et al.

Cite

CITATION STYLE

APA

Chen, B. Y., Chen, J. K., Zhu, M. Z., Zhang, D. L., Sun, J. S., Pei, J. M., … Yu, J. (2011). AC-NP: A novel chimeric peptide with natriuretic and vasorelaxing actions. PLoS ONE, 6(5). https://doi.org/10.1371/journal.pone.0020477

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free